Baird Analyst Says 'Don't 'Give Up' Yet On Gilead's Remdesivir
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) fell Thursday afternoon in reaction to a disappointing report on an early readout for its remdesivir therapy, but investors should not "give up on this